Iterum Therapeutics Faces Nasdaq Delisting on April 1st
ITRM has more than doubled off its 52-week low of $0.027 on elevated volume (52× avg).
Summary
Iterum Therapeutics plc has received official notification from Nasdaq regarding the delisting of its ordinary shares, effective April 1, 2026. This action follows the company's decision to withdraw its appeal against a previous delisting determination, primarily due to its failure to meet the minimum $1.00 bid price requirement. This news confirms the imminent end of the company's public trading on Nasdaq and aligns with the company's recent filing on March 27 to wind up its operations in Ireland. The delisting is a critical negative event, signaling severe financial distress and likely resulting in a complete loss of value for current shareholders. Investors should monitor the formal cessation of trading and the ongoing winding-up proceedings.
At the time of this announcement, ITRM was trading at $0.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.03 to $1.42. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.